Bicara Therapeutics Stock Price, News & Analysis

Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, has announced its participation in three major upcoming healthcare investor conferences in September 2025.

The company will present at the Cantor Global Healthcare Conference (September 3, 10:55 a.m. ET), the Wells Fargo Healthcare Conference (September 3, 2:15 p.m. ET), and the Morgan Stanley Global Healthcare Conference (September 8, 4:05 p.m. ET). All fireside chat presentations will be available via webcast through Bicara's Investor Relations website.

Bicara Therapeutics (NASDAQ:BCAX) reported Q2 2025 financial results and provided updates on its lead drug candidate ficerafusp alfa. The company highlighted strong Phase 1/1b trial results presented at ASCO 2025, showing a 54% confirmed objective response rate in HPV-negative head and neck cancer patients, with median duration of response of 21.7 months.

The company maintains a robust financial position with $436.6 million in cash, expected to fund operations into H1 2029. Q2 2025 saw increased R&D expenses of $24.8 million and a net loss of $27.4 million. The ongoing pivotal Phase 2/3 FORTIFI-HN01 trial continues enrollment, with additional Phase 1/1b expansion cohort data expected by Q1 2026.

Rice Biotech Launch Pad has appointed Carolyn Ng, a business unit partner at TPG Life Sciences Innovations, to its external advisory board. Ng brings significant expertise in biotech and company building, with extensive experience guiding early to midstage companies across various therapeutic areas.

Currently leading investments at TPG Life Sciences Innovations in San Francisco, Ng serves on multiple boards including Mbrace Therapeutics, Adcendo Aps, and Bicara Therapeutics (NASDAQ: BCAX). Her appointment marks her as the 16th member of the Launch Pad's external advisory board, joining leaders from various prestigious institutions and companies.

The Rice Biotech Launch Pad, based in Houston, focuses on accelerating the translation of Rice University's health and medical technology discoveries into practical medical solutions.

Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, announced its upcoming participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management team will engage in a fireside chat scheduled for Tuesday, June 10, 2025, at 3:20 p.m. ET. Investors and interested parties can access the live presentation through the Events and Presentations section of Bicara's Investor Relations website. A recording of the webcast will be made available for later viewing on the company's website.

Bicara Therapeutics (NASDAQ: BCAX) presented promising Phase 1/1b trial results for ficerafusp alfa combined with pembrolizumab in first-line recurrent/metastatic HPV-negative head and neck cancer at ASCO 2025. The trial demonstrated impressive efficacy with a median duration of response of 21.7 months and 80% of responders achieving deep responses (≥80% tumor shrinkage). Key results include a 54% confirmed objective response rate, 21% complete response rate, median overall survival of 21.3 months, and a 2-year overall survival rate of 46%. The drug, a first-in-class bifunctional antibody targeting EGFR and TGF-β, showed a manageable safety profile. These results support the advancement of FORTIFI-HN01, the company's pivotal Phase 2/3 trial in first-line recurrent/metastatic setting.

Bicara Therapeutics (NASDAQ: BCAX) has announced updated interim data from their Phase 1/1b trial of ficerafusp alfa in combination with pembrolizumab for first-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The data will be presented at the 2025 ASCO Annual Meeting. Key results from the HPV-negative population (n=28) include:

• 64% objective response rate, with 21% achieving complete response
• Median progression-free survival of 9.8 months
• 12-month overall survival rate of 61%
• Median overall survival exceeding 20 months (not yet reached)

Ficerafusp alfa, a first-in-class bifunctional antibody, targets EGFR and TGF-β to enhance tumor penetration. The safety profile remains consistent with previous findings, and biomarker data shows encouraging TGF-β inhibition. The company will host a conference call on June 1, 2025, to discuss the complete dataset.

Bicara Therapeutics (NASDAQ: BCAX) reported its Q1 2025 financial results and provided updates on its clinical programs. The company's lead drug candidate, ficerafusp alfa, a first-in-class dual-action bifunctional EGFR/TGF-β antibody, continues to advance in clinical trials. The company is currently conducting FORTIFI-HN01, a pivotal Phase 2/3 trial for first-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

Updated data from the ongoing Phase 1/1b trial will be presented at the 2025 ASCO Annual Meeting. The company reported $462.1 million in cash and cash equivalents as of March 31, 2025, expected to fund operations into first half of 2029. Q1 2025 saw a net loss of $36.8 million, with R&D expenses of $34.3 million and G&A expenses of $7.5 million.

Bicara Therapeutics presented multiple datasets for their lead drug ficerafusp alfa at the AACR Annual Meeting 2025. The drug is a first-in-class bifunctional antibody targeting EGFR and TGF-β across various solid tumors.

Key highlights:

• In head and neck cancer trials, the drug showed effectiveness in blocking TGF-β signaling and preventing drug resistance
• For skin cancer patients, the drug achieved a 30.4% overall response rate and 82.6% clinical benefit rate in previously treated patients
• Median progression-free survival reached 7.0 months in skin cancer patients
• Common side effects included skin-related issues and fatigue

The company also presented promising preclinical data showing ficerafusp alfa's potential to overcome resistance to KRAS-G12C inhibitors in lung cancer treatment. These results support the drug's broad therapeutic potential across multiple solid tumor types, particularly in combination with other cancer therapies.

Bicara Therapeutics (Nasdaq: BCAX) announced it will present updated data from its ongoing Phase 1/1b clinical trial of ficerafusp alfa at the 2025 ASCO Annual Meeting. The presentation will focus on the drug's application in first-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

Ficerafusp alfa is a first-in-class bifunctional antibody targeting both EGFR and TGF-β, being evaluated across multiple solid tumor types. The data, to be presented on June 1, 2025, will showcase updated survival and durability results specifically for HPV-negative R/M HNSCC patients, who typically face worse prognosis and poorer outcomes compared to HPV-positive cases.